Next Phase Newsletter

The firm is Canada’s leading healthcare VC Firm. Based in Toronto, the firm typically makes equity investments into digital health and AI enabled medical device companies at seed / series A-B stages and follow on rounds. The typical investment size ranges from $1.5 million to $ 7 million. The firm seeks to invest in approx. 2-5 digital health/AI enabled medical device companies per year and focuses on companies based in North America, Europe and the GCC region. 

The firm is currently looking for new investment opportunities in the Digital Health and AI enabled Medical Device spaces. The firm is opportunistic in terms of indications. The firm prefers to invest in non-invasive device companies with clinical validation and some in-human data with a clear path to clinical adoption & reimbursement. For Digital Health, the firm prefers to invest in companies developing data platforms aimed at improving outcomes or processes, with first market pilots complete and approx. $250k ARR. 

The firm seeks to invest in private companies. The firm considers pre-revenue companies, depending on sector and in companies who have has a strong commercial and technical management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

The firm is an agetech-focused seed-stage VC firm, founded in 2016 and based in New York. The firm is focused on all aspects of agetech, whether helping older adults live at home longer, assisting caregivers or facilities in elder care. Within healthcare, the firm invests in companies such as digital health, digital therapeutics, and remote monitoring, among others. The firm currently invests in companies in North America, Europe and Israel, and will soon invest in Asia and the South Pacific as well. The firm generally invests $50-150K in companies that have demonstrated early signs of market traction, and may invest up to $300K over the lifetime of the investment. 

The firm will consider investments in any technology relating to agetech that does not require clinical trials. This can include companies developing technologies relating to remote monitoring, those assisting caregivers, digital therapeutics, among others. 

The firm generally co-invests. They can be as involved as the company requires, taking a more active role if they can be of assistance to the company in any way. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A venture capital firm founded in China with over $4 billion in total managed assets in the areas of healthcare, technology and internet, and cleantech has invested in more than 70 healthcare companies, that span most sectors of life sciences from pharmaceuticals and medical devices to healthcare IT, diagnostics and select healthcare services.

The firm’s US fund is focused on early-stage health care opportunities in the US with potential market opportunities in China, and the USA team is spread out across multiple locations across the country. The firm intends to lead, co-lead, or co-invest in US-based private companies in biotech for therapeutics, Medtech, and digital health technologies, with equity investments ranging from $5 to $20 million. The firm will not make public company investments.

The firm is open to many sectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is most interested in breakthrough products and technologies that address a large unmet need. The firm seeks investments in 510K devices and will invest in devices in the PMA pathway depending on stage, preferably clinical or later. In therapeutics, the firm is modality-agnostic but generally seeking opportunities that are past the pre-clinical stage. The firm is also interested in enabling technologies for drug discovery and development, and other healthcare-related technologies in the “digital-health” space.

The firm is seeking to invest in companies with novel ideas and technology and experienced and passionate management. Given the firm’s slogan of “inspiring people with the wisdom to succeed with diligence,” The firm’s team is “hands-on” and typically assumes a board seat after an investment. In general, the firm invests globally and prefers companies that have upside opportunities in China and can leverage the firm’s China network and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An evergreen venture fund based in the US is a flexible investor; the firm’s initial allocations vary depending on the company’s developmental stage, from $150,000 to several million dollars. The firm is open to being a lead investor, and will consider opportunities globally. The firm is open to investing in both privately held companies and publicly traded companies.

The firm invests in the therapeutics sector. The firm only invests in companies with assets that are at the clinical phase of development, and which are based on solidly vetted science. The firm is agnostic in therapeutic indications and will consider opportunities in any area of medicine.

The firm likes to invest as part of a syndicate in science at a US or OUS company that will create a value inflection from a well executed study. The firm has a flexible approach to management teams and may be a more hands-on investor if the management team has limited business experience. The firm requires a high level of transparency from portfolio companies, and guides portfolio companies in planning studies that will create real value inflection points for the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of one of the largest non-profit health systems in the seeks to foster the commercialization of internal ideas as well as external innovation. To date, the firm has been focusing in Series A to B rounds but expect to look into more early-stage opportunities in the future. Initial size of investment can range from $500K – 1M. The firm invests off a balance sheet and has no dedicated fund. The firm is focused on partnering and investing in companies based in the USA.

The firm is interested in piloting and investing in technologies that strategically align with the interests of a large integrated delivery network. This includes both the organization’s existing priority areas, along trying to improve the health system’s strategic position in the future. Areas of interest include improving the ratings and member retention in our Medicaid and Medicare Advantage insurance plans, recruiting and retaining clinicians, process optimization, the coming consumerization of healthcare, back-office optimization, and more. The firm is primarily looking for digital health solutions, but will consider some 510k medical devices. The firm is not interested in therapeutics or diagnostics.

The firm has no specific company or management team requirements. The firm prefers to co-invest alongside syndicate partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor and venture builder based in the USA invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in Infectious Disease technologies to partner and or invest with a current portfolio company. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe and Israel.

The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.

The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused Venture Capital and Growth Equity firm currently manages ~$1 billion, providing $15-$50 million of equity capital per company over the life of the investment. With offices in USA and Europe, the firm is primarily looking for companies throughout North America and Europe.

The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, life sciences tools, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is open in terms of indications.

The firm looks for management teams that are very willing to work alongside them, and the firm generally looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.